Eye Protein Levels Linked to Cognitive Decline
A recent study has shed light on the intriguing connection between SLIT2 protein levels in the eye and cognitive performance, particularly in middle-aged adults. The research findings revealed a correlation between lower SLIT2 levels in the vitreous humor and poorer memory and overall cognition, while higher SLIT2 levels in plasma were associated with decreased cognitive scores. This discovery underscores the potential of utilizing eye-based biomarkers for early detection of cognitive impairments, such as dementia and Alzheimer’s disease.
Neurocognitive impairments are characterized by pathological changes that have the potential to cause damage to neural tissue. One common occurrence in neurodegenerative disorders is the accumulation of proteins leading to pathological alterations. While previous studies have hinted at a relationship between SLIT2 protein levels and the onset of dementia and Alzheimer’s disease, these findings lacked validation due to the absence of a commercially available SLIT2 immunoassay. Moreover, there is a dearth of published data on SLIT2 protein levels in individuals with early-onset dementia.
A groundbreaking study conducted by researchers at the Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center has demonstrated a significant association between SLIT2 protein levels in both vitreous humor (the gel-like substance in the eye) and plasma (blood) and neurocognitive test results in middle-aged subjects. This study marks the first of its kind to report the relative concentrations of SLIT2 in vitreous humor and plasma, establishing a clear link between SLIT2 levels from these sources and cognitive function.
Dr. Manju L. Subramanian, an associate professor of ophthalmology at the school, emphasized the novelty of the findings, stating, “The association between SLIT2, which is highly expressed in the eye’s retina, and cognitive status has not been previously investigated. Our findings demonstrate the potential of ocular fluids as a sampling source for early detection and diagnosis of neurodegenerative diseases.”
Seventy-nine individuals, with an average age of 56, underwent both eye surgery and neurocognitive evaluations as part of the study. Samples of their vitreous humor and plasma were collected and analyzed using a custom-designed, highly sensitive Meso Scale Discovery (MSD) SLIT2 electrochemiluminescence immunoassay. This assay leverages antigen-antibody reactions to quantify the presence and concentration of specific substances in biological samples. The analysis of SLIT2 levels in vitreous humor and plasma was conducted using GraphPad Prism.
The study revealed that lower SLIT2 levels in vitreous humor were linked to lower scores on the Montreal Cognitive Assessment (MoCA), a cognitive impairment screening tool, as well as the Immediate Recall Verbatim z-score, a metric of verbal memory. Conversely, higher SLIT2 levels in plasma were associated with reduced MoCA scores. Notably, the vitreous humor contained significantly higher levels of SLIT2 compared to plasma, with up to a seven-fold difference. Importantly, the levels of SLIT2 in vitreous humor and plasma did not exhibit a correlation with each other.
Dr. Weining Lu, an associate professor of medicine, pathology, and laboratory medicine at the school, highlighted the robustness of the findings, stating, “We found the association between SLIT2 levels and neurocognitive scores remains significant even after accounting for various demographic factors like age, sex, race, and health conditions such as diabetic status, diabetic retinopathy, glaucoma, and Apolipoprotein E (APOE) genotype.”
These compelling findings were published online in the Journal of Alzheimer’s Disease and were presented as an abstract at the 2025 ARVO Annual Meeting held in Salt Lake City, Utah, in May of that year.
This research received support from various sources, including the National Institutes of Health, the Department of Defense, Boston University Ignition Award, the Evans Center of Boston University, and the Boston University Undergraduate Research Opportunities Program.
The study’s significant results underscore the potential of SLIT2 as a sensitive biomarker for detecting mild cognitive impairment and early dementia, warranting further investigation into its utility in clinical settings. The findings pave the way for leveraging eye-based biomarkers for early cognitive impairment detection, potentially revolutionizing the field of neurodegenerative disease diagnosis and treatment.
Key Takeaways:
- SLIT2 protein levels in the eye and blood are linked to cognitive performance.
- Lower SLIT2 levels in vitreous humor correlate with poorer memory and cognition.
- Higher SLIT2 levels in plasma predict lower cognitive scores.
- Eye-based biomarkers show promise for early detection of neurodegenerative diseases.
Read more on neurosciencenews.com